Ali Jabbari

List of Publications by Year
in descending order

34	3,103	361413 20	414414 32
papers	citations	h-index	g-index

37	37	37	3460
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Single-cell analysis of SÃ©zary syndrome reveals novel markers andÂshifting gene profiles associated with treatment. Blood Advances, 2023, 7, 321-335.	5.2	7
2	The current state of knowledge of the immune ecosystem in alopecia areata. Autoimmunity Reviews, 2022, 21, 103061.	5.8	6
3	201â€...Type I interferon modulates langerhans cell ADAM17 in lupus to contribute to photosensitivity. , 2021, , .		0
4	Integrative analysis of rare copy number variants and gene expression data in alopecia areata implicates an aetiological role for autophagy. Experimental Dermatology, 2020, 29, 243-253.	2.9	21
5	Factors associated with insurance coverage of tofacitinib for alopecia areata: A retrospective review from an academic institution. Journal of the American Academy of Dermatology, 2020, 83, 1509-1510.	1.2	4
6	A transcriptomic map of murine and human alopecia areata. JCI Insight, 2020, 5, .	5.0	7
7	Pretibial dystrophic epidermolysis bullosa associated with aberrant exon splicing of type VII collagen. JAAD Case Reports, 2019, 5, 779-781.	0.8	2
8	IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans. Journal of Allergy and Clinical Immunology, 2019, 144, 1731-1734.e1.	2.9	19
9	Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression. Clinical Cancer Research, 2019, 25, 2996-3005.	7.0	80
10	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosusâ€"An Ongoing Need for International Consensus and Collaborations. Journal of Investigative Dermatology, 2019, 139, 270-276.	0.7	18
11	An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis. Journal of Investigative Dermatology, 2018, 138, 1539-1545.	0.7	133
12	High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata. JCI Insight, 2018, 3, .	5.0	42
13	Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight, 2016, 1, e89776.	5.0	243
14	Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight, 2016, 1, e89790.	5.0	210
15	Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Experimental Dermatology, 2016, 25, 642-643.	2.9	71
16	Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. EBioMedicine, 2016, 7, 240-247.	6.1	70
17	CXCR3 Blockade Inhibits T Cell Migration into the Skin and Prevents Development of Alopecia Areata. Journal of Immunology, 2016, 197, 1089-1099.	0.8	65
18	Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). Journal of the American Academy of Dermatology, 2016, 74, 370-371.	1.2	162

#	Article	IF	Citations
19	Master Regulators of Infiltrate Recruitment in Autoimmune Disease Identified through Network-Based Molecular Deconvolution. Cell Systems, 2015, 1, 326-337.	6.2	20
20	Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine, 2015, 2, 351-355.	6.1	200
21	Ruxolitinib Attenuates Cutaneous Lupus Development in a Mouse Lupus Model. Journal of Investigative Dermatology, 2015, 135, 1912-1915.	0.7	29
22	Dominant Th1 and Minimal Th17 Skewing in Discoid Lupus Revealed by Transcriptomic Comparison with Psoriasis. Journal of Investigative Dermatology, 2014, 134, 87-95.	0.7	95
23	Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nature Medicine, 2014, 20, 1043-1049.	30.7	697
24	Genetic Basis of Alopecia Areata. Dermatologic Clinics, 2013, 31, 109-117.	1.7	44
25	Transcriptional Profiling of Psoriasis Using RNA-seq Reveals Previously Unidentified Differentially Expressed Genes. Journal of Investigative Dermatology, 2012, 132, 246-249.	0.7	94
26	Erosive plaques on the dorsal surfaces of the hands. Journal of the American Academy of Dermatology, 2012, 66, e31-e32.	1.2	0
27	Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the â€œCoreâ€•Pathogenesis of Disease. PLoS ONE, 2012, 7, e44274.	2.5	149
28	A Role for IFN-Î³ from Antigen-Specific CD8+ T Cells in Protective Immunity toListeria monocytogenes. Journal of Immunology, 2007, 179, 2457-2466.	0.8	32
29	Simultaneous assessment of antigen-stimulated cytokine production and memory subset composition of memory CD8 T cells. Journal of Immunological Methods, 2006, 313, 161-168.	1.4	24
30	Secondary memory CD8+ T cells are more protective but slower to acquire a centralâ€“memory phenotype. Journal of Experimental Medicine, 2006, 203, 919-932.	8.5	148
31	The generation and modulation of antigen-specific memory CD8 T cell responses. Journal of Leukocyte Biology, 2006, 80, 16-23.	3.3	13
32	T Cell Conditioning Explains Early Disappearance of the Memory CD8 T Cell Response to Infection. Journal of Immunology, 2006, 177, 3012-3018.	0.8	18
33	Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nature Medicine, 2005, 11, 748-756.	30.7	362
34	Cutting Edge: Differential Self-Peptide/MHC Requirement for Maintaining CD8 T Cell Function versus Homeostatic Proliferation. Journal of Immunology, 2005, 175, 4829-4833.	0.8	16